Drug Profile
Risperidone - ValiSeek
Alternative Names: VAL-401Latest Information Update: 15 Feb 2022
Price :
$50
*
At a glance
- Originator Tangent Reprofiling
- Developer Valiseek
- Class Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Fluorinated hydrocarbons; Isoxazoles; Mood stabilisers; Piperidines; Pyrimidinones; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Pancreatic cancer
- No development reported Non-small cell lung cancer
Most Recent Events
- 15 Feb 2022 ValiSeek has patent protection for VAL 401 in China, Europe, Israel, Japan, Mexico, New Zealand and USA before February 2022 (ValiSeek's pipeline, February 2022)
- 15 Feb 2022 ValiSeek receives patent allowance for VAL 401 in China, Europe, Israel, Japan, Mexico, New Zealand and USA before February 2022 (ValiSeek's pipeline, February 2022)
- 15 Feb 2022 No development reported - Phase-II for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Georgia (PO) before February 2022 (ValiRx's pipeline, February 2022)